Jessica A.O. Zimmerman

Dr. Jessica A.O. Zimmerman

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Cancer Research Communications
Verified
Journal Article
Open access
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase, and the ATR–checkpoint kinase 1 (CHK1)–WEE1 signaling pathway. In this study, we identified that multiple HDAC inhibitors, including fimepinostat, romidepsin, and panobinostat, downregulate the levels of the RRM1, RRM2, CHK1, and WEE1 proteins in Ewing sarcoma cells and impair DNA replication. Moreover, transcriptome analyses identified that HDAC inhibitors downregulate the expression of multiple components of the prereplication complex, including the minichromosome maintenance complex 2–7 (MCM2–7) proteins and CDT1, that are essential for genomic DNA replication. Additionally, proteomic studies identified that HDAC inhibitors also downregulate the level of the BRD4 protein, a BET bromodomain protein that regulates both the transcriptional program of the EWS::FLI1 oncoprotein and DNA replication. Overall, these results provide novel insight into the molecular mechanisms by which HDAC inhibitors target cancer cells, regulate DNA replication, and inhibit the cellular response to DNA replication stress. Significance: In this work, we identify that HDAC inhibitors broadly disrupt DNA replication and the response to replication stress in Ewing sarcoma cells by downregulating RRM1, RRM2, CHK1, and WEE1. Notably, HDAC inhibitors also reduce MCM2–7 proteins, which are essential for prereplication complex helicase function in replication initiation and elongation, and CDT1, which loads MCM2–7 onto DNA.

8 December 2020 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
MFMimi Fang
Mimi Fang
BDBintou Doumbia
Bintou Doumbia
ANAlexis Neyman
Alexis Neyman
JCJi Hyeon Cha
Ji Hyeon Cha
MPMiles A Pufall
Miles A Pufall
Ullmann-like synthesis of deacylcortivazol-like regioisomers reveals a broader than expected structure activity relationship for novel glucocorticoids.

27 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
MFMimi Fang
Mimi Fang
MPMiles A. Pufall
Miles A. Pufall
Glucocorticoids are the cornerstone of B-lymphoblastic leukemia (B-ALL) therapy. Because response to glucocorticoids alone predicts overall outcomes for B-ALL, enhancing glucocorticoid potency should improve treatment. We previously showed that inhibition of the lymphoid-restricted PI3Kδ with idelalisib enhances glucocorticoid activity in B-ALL cells. Here, we show that idelalisib enhances glucocorticoid potency in 90% of primary B-ALL specimens and is most pronounced at sub-saturating doses of glucocorticoids near the EC50. Potentiation is associated with enhanced regulation of all glucocorticoid-regulated genes, including genes that drive B-ALL cell death. Idelalisib reduces phosphorylation of the glucocorticoid receptor (GR) at PI3Kδ/MAPK1 (ERK2) targets S203 and S226. Ablation of these phospho-acceptor sites enhances sensitivity to glucocorticoids with ablation of S226 in particular reducing synergy. We also show that phosphorylation of S226 reduces the affinity of GR for DNA in vitro. We propose that PI3Kδ inhibition improves glucocorticoid efficacy in B-ALL in part by decreasing GR phosphorylation, increasing DNA binding affinity, and enhancing downstream gene regulation. This mechanism and the response of patient specimens suggest that idelalisib will benefit most patients with B-ALL, but particularly patients with less responsive, including high-risk, disease. This combination is also promising for the development of less toxic glucocorticoid-sparing therapies.

22 December 2016 in Clinical Pediatrics
Verified
Journal Article
Closed access
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
ASAnjali Sharathkumar
Anjali Sharathkumar

27 June 2025
Verified
Other
Open access
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
HDAC inhibitors decrease RRM1, RRM2, CHK1, and WEE1 protein levels. A, EW8 and TC71 cells were treated with fimepinostat (25 or 100 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting. B, EW8 and TC71 cells were treated with LY3023414 (1,000 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting. C, EW8 and TC71 cells were treated with panobinostat (10 nmol/L) or romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting. D and E, EW8 cells were treated with different doses of panobinostat (D) or romidepsin (E) for 24 hours, and then cellular lysates were collected for immunoblotting. F, Cell lines representing additional sarcoma subtypes were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting.

27 June 2025
Verified
Other
Open access
PDF file
SKStacia L. Koppenhafer
Stacia L. Koppenhafer
EGElizabeth L. Geary
Elizabeth L. Geary
MTMary V. Thomas
Mary V. Thomas
ECEmma Croushore
Emma Croushore
JZJessica A.O. Zimmerman
Jessica A.O. Zimmerman
DGDavid Gordon
David Gordon
Genes, which are downregulated in EW8 cells treated with romidepsin, that are enriched in the Kegg Pathway DNA replication gene set.